US2012064030A1PendingUtilityA1

Methods of treating nervous system conditions

56
Assignee: JOHNSTONE BRIAN HPriority: Aug 24, 2006Filed: Sep 19, 2011Published: Mar 15, 2012
Est. expiryAug 24, 2026(~0.1 yrs left)· nominal 20-yr term from priority
A61P 25/28A61P 25/08A61P 29/00A61P 25/00A61P 25/16A61K 35/35C12N 2502/1305C12N 2502/1382C12N 2502/00C12N 2502/1358C12N 5/0667C12N 5/06C12N 5/0619C12N 2502/1352C12N 5/0663C12N 5/0668A61K 35/28
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating nervous system conditions. In at least one embodiment of a method of treating a mammalian patient having a neuronal injury or insult of the present disclosure, the method comprises the step of administering a therapeutically-effective dose of a stem cell conditioned medium to a mammalian patient, the stem cell conditioned medium comprising a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult.

Claims

exact text as granted — not AI-modified
1 . A method of treating a mammalian patient having a neuronal injury or insult, the method comprising the step of:
 administering a therapeutically-effective dose of a stem cell conditioned medium to a mammalian patient, the stem cell conditioned medium comprising a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult.   
     
     
         2 . The method of  claim 1 , wherein the neural injury or insult is selected from the group consisting of a chronic injury, an acute injury, a central nervous system injury, and a peripheral nervous system injury. 
     
     
         3 . The method of  claim 2 , wherein the acute injury is selected from the group consisting of a cerebral hypoxia, a spinal cord injury, a brain injury, and inflammation. 
     
     
         4 . The method of  claim 2 , wherein the central nervous system injury is selected from the group consisting of a brain injury and a spinal cord injury. 
     
     
         5 . The method of  claim 1 , wherein the neural injury or insult comprises a neurodegenerative disorder. 
     
     
         6 . The method of  claim 5 , wherein the neurodegenerative disorder is selected from the group consisting of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, cerebral palsy, peripheral neuropathy, Huntington's disease, epilepsy, encephalomyelitis, encephalitis, a spinal cord injury, a brain injury, and cerebral hypoxia. 
     
     
         7 . The method of  claim 1 , wherein the neural injury or insult comprises a hypoxia-ischemia of the brain selected from the group consisting of neonatal cerebral hypoxia and adult cerebral hypoxia. 
     
     
         8 . The method of  claim 1 , wherein the step of administering is performed by administering a therapeutically effective dose of a stem cell conditioned medium to a mammalian patient selected from the group consisting of a neonatal patient, a child, an adolescent, and an adult patient. 
     
     
         9 . The method of  claim 1 , wherein the step of administering is performed by systemically administering a therapeutically effective dose of a stem cell conditioned medium to a mammalian patient. 
     
     
         10 . The method of  claim 9 , wherein the systemic administration is selected from the group consisting of injection administration and intravenous administration. 
     
     
         11 . The method of  claim 1 , wherein the step of administering is performed by locally administering a therapeutically effective dose of a stem cell conditioned medium to a mammalian patient at or near a site of neural injury or insult. 
     
     
         12 . The method of  claim 11 , wherein the local administration is selected from the group consisting of interarterial administration, intravenous intraparenchymal administration, intrathecal administration, and interperitoneal administration. 
     
     
         13 . The method of  claim 1 , wherein the step of administering is performed to treat a mammalian neural injury or insult by treating neural cells in vivo that are at risk for hypoxia induced neuronal death. 
     
     
         14 . The method of  claim 1 , wherein the step of administering is performed to treat a mammalian neural injury or insult by treating cerebral tissues damaged by hypoxia. 
     
     
         15 . The method of  claim 1 , wherein the step of administering is performed to treat a mammalian neural injury or insult by stimulating neural cell regeneration. 
     
     
         16 . The method of  claim 1 , wherein the cell culture supernatant is produced by culturing at least one mammalian adipose stem cell to produce the at least one factor. 
     
     
         17 . A method of treating a mammalian patient having a neuronal injury or insult, the method comprising the step of:
 administering a therapeutically-effective dose of a stem cell conditioned medium to a mammalian patient, the stem cell conditioned medium comprising a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult selected from the group consisting of a chronic injury, an acute injury, a central nervous system injury, a peripheral nervous system injury, and a neurodegenerative disorder.   
     
     
         18 . A method of treating a mammalian patient having a neuronal injury or insult, the method comprising the step of administering a therapeutically-effective dose of a medium containing at least one factor derived from a mammalian stem cell to a mammalian patient to treat a mammalian neural injury or insult. 
     
     
         19 . The method of  claim 18 , wherein the mammalian stem cell comprises a human mammalian stem cell, and wherein the mammalian patient comprises a human patient, and wherein the human mammalian stem cell was obtained from the human patient. 
     
     
         20 . The method of  claim 18 , wherein the mammalian stem cell comprises an animal mammalian stem cell, and wherein the mammalian patient comprises an animal patient, and wherein the animal mammalian stem cell was obtained from the animal patient.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.